13. Pharmacoeconomics. 2018 Apr;36(4):505. doi: 10.1007/s40273-018-0634-5.Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive BreastCancer in Iran: A Cost-Effectiveness and Scenario Analysis for an OptimalTreatment Strategy.Ansaripour A(1), Uyl-de Groot CA(2), Redekop WK(2).Author information: (1)Institute for Medical Technology Assessment, Institute of Health Policy andManagement, Erasmus University Rotterdam, PO Box 1738, 3000 DR, Rotterdam, TheNetherlands. ansaripour@bmg.eur.nl.(2)Institute for Medical Technology Assessment, Institute of Health Policy andManagement, Erasmus University Rotterdam, PO Box 1738, 3000 DR, Rotterdam, TheNetherlands.Erratum for    Pharmacoeconomics. 2018 Jan;36(1):91-103.ABSTARCT: Page 95, TableÂ 2, final row, second column: the mean Advanced treatmentannual cost which.DOI: 10.1007/s40273-018-0634-5 PMID: 29476362 